Evaluation of the Pastocovac (COVID-19 vaccine) efficacy following autologous stem cell transplantatio
Phase 2
Recruiting
- Conditions
- Condition 1: Autologous stem cell transplantation. Condition 2: SARS-CoV-2 vaccine efficacy.SARS-CoV-2 vaccine effectiveness
- Registration Number
- IRCT20140818018842N23
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 124
Inclusion Criteria
?All autologous stem cell transplantation
Age >=18
Exclusion Criteria
patients who received Rituximab during the past six months.
Patients who do not consent to vaccination after transplantation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SARS-CoV-2 specific IgG (anti-S1) titer. Timepoint: Four weeks after the second vaccine. Method of measurement: Enzyme-linked immunosorbent assay.
- Secondary Outcome Measures
Name Time Method SARS-CoV-2 specific IgG (anti-S1) titer. Timepoint: Four weeks after the first vaccine. Method of measurement: ?Enzyme-linked immunosorbent assay.;Cumulative incidence of COVID-19. Timepoint: 12 months following bone marrow transplantation. Method of measurement: RT-PCR test.